Michael Kim, MD, on Developing More CREB Inhibitors in Pancreatic Cancer Moving Forward

Video

Kim discussed the need for further CREB inhibitor combinations to target collateral pathways and improve patient outcomes.

Michael Kim, MD, of The University of Texas MD Anderson Cancer Center, spoke with CancerNetwork® at the virtual American Association for Cancer Research Annual Meeting 2021 about the need for more CREB inhibitors to effectively treat patients with pancreatic cancer moving forward.

Transcription:

Work moving forward should figure out what other drugs can be combined with the CREB inhibitor we used [in our study]. There’s only one we could find, so the development of additional CREB inhibitors would be a great step forward. Also, understanding how we can mix other drugs with CREB inhibitors to shut down other collateral pathways important in KRAS signaling [will be essential]. The combination of those 2 might really lead to improved patient outcomes and a better mechanistic understanding of how mutant TP53 and KRAS can be divided and then individually conquered to fight this disease.

Reference:

Kim MP, Li X, Deng J, et al. Mutant p53 and oncogenic KRAS converge on CREB1 to drive pancreatic cancer metastasis. Presented at: AACR Annual Meeting 2021; April 10-15, 2021; virtual. Abstract 2417.

Recent Videos
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Related Content